Blog

See the largest ongoing interventional idiopathic pulmonary fibrosis (IPF) drug trials ranked by reported study enrollment on ClinicalTrials.gov, featuring phase 2 and 3 studies from Bristol-Myers Squ...

Analyze 123 orphan-designated novel drug approvals by FDA CDER between 2021 and 2025 classified across 12 therapeutic areas, led by oncology, metabolic diseases, and neurology.

Examine ten landmark FDA-approved rare disease therapies spanning monoclonal antibodies, small molecules, RNA-targeted therapies, and gene editing across conditions like PNH, cystic fibrosis, SMA, and...

A practical guide to the FDA rare disease drug development pathway, clarifying statutory criteria, the distinction between orphan designation and marketing approval, trial design flexibility, and orph...

Explore selected FDA-approved orphan drugs from ACADIA, BioMarin, Novartis, Sarepta, and Servier between 2021 and 2025, detailing approved rare disease indications, patient populations, and regulatory...

See which U.S. states reported the most Medicaid GLP-1 prescriptions in 2025 based on CMS State Drug Utilization Data, featuring volume rankings alongside prescription-mix rates per 1,000 outpatient f...

See which GLP-1 and dual GIP/GLP-1 receptor agonist medications led the nation in reported Medicaid-reimbursed prescriptions in 2025 across 11.2 million aggregate fills, led by Ozempic, Wegovy, and Tr...

See confirmed GLP-1 price changes taking effect January 1, 2027, comparing Novo Nordisk's $675 monthly list price/WAC against CMS's $274 Medicare single Maximum Fair Price per 30-day-equivalent supply...

See which current FDA drug shortage entries have the oldest initial posting dates based on the October 2026 CDER listing. The ranking measures elapsed calendar days from initial posting across active ...

See which pharmaceutical manufacturers are associated with the most active FDA drug shortage entries based on the October 2026 CDER export. The ranking evaluates distinct company–entry pairs across 1,...

See the most frequently reported shortage reasons across current FDA drug shortage presentation records in 2026. The ranking evaluates populated reason categories across 1,140 current presentation rec...

See which states lead in non-exempt clinical laboratories holding a CLIA Certificate of Accreditation based on CMS’s September 2026 report. The ranking covers the 50 US states, evaluating 15,333 accre...